First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma PatientsTreated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Details

Language :

English

Database :

OpenAIRE

Journal :

D'Amore, F A, Leppä, S, Gomes da Silva, M, Relander, T, Brown, P D N, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, Van Gelder, M, Doorduijn, J, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, U-M, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nösslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, I, Salek, D, Jyrkkiö, S, Prochazka, V, Zijlstra, J, Böhmer, L, Greil, R, Stevens, W, Fijnheer, R, van Marwijk, M, Grube, M, Trümper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Jantunen, E, Hopfinger, G, Van den Neste, E & Toldbod, H 2012, ' First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma PatientsTreated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy ', Blood, vol. 120, no. 57 .

Accession number :

edsair.pure.au.......25626fa6e1ac951636eb69a7f59d4992